Clinical Trials

Many of our members are physicians who have worked as principal investigators for a wide variety of clinical trials for allergic diseases such as food allergies, eczema, chronic spontaneous urticaria, eosinophilic esophagitis, etc. These physicians have worked to coordinate clinical trials for pharmaceutical sponsors such as AstraZeneca, Bristol Myers Squibb, Celgene, Ellodi, and Allakos among many others. 

Each physician in this organization works with a large volume of patients with a variety of allergic diseases. For companies looking for recruitment in their clinical trials, our network of physicians can enhance the ability of trials to recruit participants. Our access to this large patient network benefits both the companies sponsoring the research, as well as patients who have exhausted standard of care options with minimal results for treatment of their conditions. We hope to expand the number of clinical trials that we are able to coordinate at our sites to further medical research and the quality of the patient care that we can provide. 

For pharmaceutical companies looking for potential clinical trial sites and principal investigators, our society provides great options given the extensive research and clinical experience of these physicians. The practices listed also have experienced clinical research coordinators and knowledgeable staff members that are experienced in clinical research. Regardless of their involvement as research coordinators, the staff members working under these physicians have extensive exposure and experience with clinical trials, and they are able to provide our patient populations with information about research and what it would mean to be a part of a clinical trial. Additionally, as non-academically affiliated sites with IRB certification, we are able to accommodate and initiate multiple clinical trials very efficiently.  

John Leung , MD, AGAF, FACAAI: Research and Clinical Trials

Deborah Pedersen, MD, MS:

Pedersen/ Allergy & Asthma Care, PC: Research conducting site -  A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old Children with Peanut Allergy.